We are live on
!
Find out more
DekaBank Deutsche Girozentrale Portfolio holdings
AUM
$59.2B
1-Year Est. Return
26.02%
This Fund
S&P 500
This Quarter
Est. Return
-11.33%
1 Year Est. Return
+26.02%
3 Year Est. Return
+92.08%
5 Year Est. Return
+125.09%
10 Year Est. Return
+457.34%
AUM
$15.1B
AUM Growth
-$1.81B
(-11%)
Cap. Flow
+$464M
Cap. Flow
% of AUM
3.07%
Top 10 Holdings %
Top 10 Hldgs %
22.68%
Holding
1,302
New
77
Increased
452
Reduced
571
Closed
126
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Linde
LIN
|
+$835M |
| 2 |
Procter & Gamble
PG
|
+$87.9M |
| 3 |
Alibaba
BABA
|
+$50.4M |
| 4 |
Merck
MRK
|
+$47.1M |
| 5 |
Target
TGT
|
+$42.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$105M |
| 2 |
Texas Instruments
TXN
|
+$79.4M |
| 3 |
TSMC
TSM
|
+$77.5M |
| 4 |
Cisco
CSCO
|
+$55.8M |
| 5 |
NextEra Energy
NEE
|
+$47.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.2% |
| 2 | Healthcare | 16.02% |
| 3 | Financials | 13.93% |
| 4 | Communication Services | 9.97% |
| 5 | Consumer Discretionary | 8.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
926
Pacific Biosciences
PACB
$370M
| $279K | ﹤0.01% |
37,500
-8,500
| -18% | -$53.9K |
|
927
Xerox
XRX
$425M
| $268K | ﹤0.01% |
12,812
-84,337
| -87% | -$2.16M |
|
|
EGRX
928
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $268K | ﹤0.01% |
6,900
-1,600
| -19% | -$82.5K |
|
929
uniQure
QURE
$3.22B
| $261K | ﹤0.01% |
10,100
-2,200
| -18% | -$61.2K |
|
930
Polaris
PII
$4.07B
| $256K | ﹤0.01% |
3,172
-3,385
| -52% | -$304K |
|
931
Enanta Pharmaceuticals
ENTA
$400M
| $253K | ﹤0.01% |
3,550
-850
| -19% | -$65.2K |
|
|
HA
932
DELISTED
Hawaiian Holdings, Inc.
HA
| $253K | ﹤0.01% |
9,700
-4,700
| -33% | -$159K |
|
|
UBX
933
DELISTED
Unity Biotechnology
UBX
| $252K | ﹤0.01% |
+1,500
| New | +$199K |
|
934
Antero Resources
AR
$10.7B
| $251K | ﹤0.01% |
25,387
+2,618
| +11% | +$38.7K |
|
935
BioCryst Pharmaceuticals
BCRX
$2.4B
| $251K | ﹤0.01% |
31,500
-7,000
| -18% | -$54.4K |
|
|
APTX
936
DELISTED
Aptinyx Inc. Common Stock
APTX
| $249K | ﹤0.01% |
+15,000
| New | +$355K |
|
937
Atara Biotherapeutics
ATRA
$76.1M
| $248K | ﹤0.01% |
288
-64
| -18% | -$59.4K |
|
|
LKFT
938
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
| $247K | ﹤0.01% |
2,800
-3,400
| -55% | -$345K |
|
|
VRNT
939
DELISTED
Verint Systems
VRNT
| $247K | ﹤0.01% |
11,429
+7,042
| +161% | +$162K |
|
940
American Airlines Group
AAL
$10.6B
| $245K | ﹤0.01% |
7,311
+468
| +7% | +$16.3K |
|
|
NAV
941
DELISTED
Navistar International
NAV
| $245K | ﹤0.01% |
9,440
| – | – |
|
942
Banco Bradesco
BBD
$36.7B
| $244K | ﹤0.01% |
40,216
| – | – |
|
943
Werner Enterprises
WERN
$2.25B
| $243K | ﹤0.01% |
8,100
-1,100
| -12% | -$35.9K |
|
|
ATNX
944
DELISTED
Athenex, Inc. Common Stock
ATNX
| $241K | ﹤0.01% |
940
-205
| -18% | -$52.2K |
|
945
Open Text
OTEX
$6.04B
| $233K | ﹤0.01% |
7,164
+1,987
| +38% | +$67.1K |
|
|
DRNA
946
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $233K | ﹤0.01% |
+23,000
| New | +$303K |
|
947
Grupo Aeroportuario del Sureste
ASR
$8.3B
| $231K | ﹤0.01% |
1,496
| – | – |
|
|
RDUS
948
DELISTED
Radius Health, Inc.
RDUS
| $229K | ﹤0.01% |
15,800
-173,600
| -92% | -$2.92M |
|
|
AMAG
949
DELISTED
AMAG Pharmaceuticals
AMAG
| $227K | ﹤0.01% |
14,850
-3,300
| -18% | -$62.9K |
|
|
HSII
950
DELISTED
Heidrick & Struggles
HSII
| $224K | ﹤0.01% |
+7,174
| New | +$235K |
|
Similar funds
QCM
NAMI
DekaBank Deutsche Girozentrale's Q4 2018 Portfolio in Review
As of Q4 2018, DekaBank Deutsche Girozentrale held 1,302 positions worth $15.1B, down 11% from $16.9B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
DekaBank Deutsche Girozentrale deployed $464M of net new capital in Q4 2018, opening 77 new positions and adding to 452 existing holdings. Its largest new stake was Linde: 5,283,074 shares worth $840M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Johnson & Johnson, an estimated $105M trimmed.
- DekaBank Deutsche Girozentrale's largest Q4 2018 buy was Linde: 5,283,074 shares worth $840M.
- DekaBank Deutsche Girozentrale added most to Procter & Gamble in Q4 2018, an estimated $87.9M increase.
- DekaBank Deutsche Girozentrale's biggest Q4 2018 reduction was Johnson & Johnson, cutting an estimated $105M.
- DekaBank Deutsche Girozentrale fully exited Express Scripts Holding Company in Q4 2018, selling an estimated $46.5M.
- DekaBank Deutsche Girozentrale's ten largest holdings make up 23% of its $15.1B portfolio in Q4 2018.
- DekaBank Deutsche Girozentrale opened 77 new positions and closed 126 in Q4 2018.
- DekaBank Deutsche Girozentrale's portfolio value fell 11% quarter-over-quarter to $15.1B.
Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2018, filed 12 Feb 2019.